Advanced breast cancer treatment depends on whether the cancer is locally advanced or has spread to distant organs. Treatment may include chemotherapy, hormone therapy, targeted therapy, immunotherapy, surgery, radiation, antibody-drug conjugates, and supportive care.
The plan is guided by the cancer’s stage, hormone receptor and HER2 status, genetic changes, previous treatments, symptoms, affected organs, and the patient’s overall health.
Advanced Breast Cancer Treatment
Locally advanced breast cancer is often treated with medicines before surgery, followed by surgery and radiation when possible. Metastatic breast cancer usually requires ongoing systemic treatment designed to control the disease, relieve symptoms, and maintain quality of life.
| Cancer type or biomarker | Common treatment approach |
| Locally advanced stage III | Drug therapy before surgery, surgery, radiation, and additional systemic therapy |
| HR-positive, HER2-negative | Hormone therapy with a CDK4/6 inhibitor; later biomarker-directed treatments |
| HER2-positive | HER2-targeted medicines, sometimes with chemotherapy |
| HER2-low or HER2-ultralow | Selected HER2-directed antibody-drug conjugates |
| Triple-negative, PD-L1-positive | Pembrolizumab with chemotherapy for eligible patients |
| Inherited BRCA1 or BRCA2 variant | PARP inhibitor in selected cases |
| PIK3CA, AKT1, PTEN or ESR1 alteration | Targeted or endocrine treatment matched to the biomarker |
| Bone metastases | Systemic therapy, radiation, pain control and bone-modifying medicine |
| Brain metastases | Surgery, radiation and selected systemic treatments |
This is a simplified overview. The appropriate treatment and sequence must be selected by an oncology team.
What Does Advanced Breast Cancer Mean?
The term advanced breast cancer may describe two different situations.
Locally advanced breast cancer has spread extensively within the breast, skin, chest wall, or nearby lymph nodes but has not been found in distant organs. It is commonly classified as stage III breast cancer.
Metastatic breast cancer, also called stage IV breast cancer, has spread to distant areas such as the bones, liver, lungs, or brain. Cancer found in these organs is still breast cancer because the metastatic cells originated in the breast.
This distinction matters because locally advanced disease may still be treated with curative intent. Metastatic breast cancer is generally managed as a long-term, life-limiting illness, with treatment focused on disease control and quality of life.
How Locally Advanced Breast Cancer Is Treated?
Treatment for stage III breast cancer often begins with systemic therapy before surgery. This is called neoadjuvant treatment, and its purpose is to shrink the tumor, address cancer cells elsewhere in the body, and make surgery more effective.
The specific treatment depends on breast cancer subtype:
- HER2-positive cancer may receive chemotherapy with HER2-targeted medicines.
- Triple-negative cancer may receive chemotherapy combined with immunotherapy when appropriate.
- Hormone receptor-positive cancer may receive chemotherapy or, in selected patients, hormone-based treatment.
After the tumor responds, surgery may involve a mastectomy or breast-conserving procedure with lymph-node evaluation. Radiation therapy and additional drug treatment may be recommended based on the surgical findings and remaining cancer.
How Metastatic Treatment Is Selected?
Systemic treatment is central to stage IV breast cancer care because medicines can reach cancer cells throughout the body. Surgery and radiation are generally reserved for specific tumors, symptoms, or complications.
When choosing advanced breast cancer treatment, doctors consider estrogen and progesterone receptor status, HER2-positive, HER2-low or HER2-ultralow findings, PD-L1 expression, and inherited BRCA1 or BRCA2 variants. PIK3CA, AKT1, PTEN and ESR1 alterations may also help identify suitable targeted therapies. Previous breast cancer treatments, metastatic locations, cancer growth rate, menopausal status, symptoms, organ function, and the patient’s goals and treatment preferences all shape the personalized treatment plan.
Whenever possible, doctors may biopsy a metastatic tumor. Its ER, PR or HER2 status can differ from the original cancer, potentially changing the treatment plan. Blood-based liquid biopsy may also identify relevant genetic alterations.
HR-Positive, HER2-Negative Breast Cancer
Hormone receptor-positive breast cancer grows partly in response to estrogen or progesterone. Treatment often begins with endocrine therapy combined with a targeted medicine known as a CDK4/6 inhibitor.
Hormone treatments may include an aromatase inhibitor, fulvestrant, tamoxifen, or an oral estrogen receptor-targeting drug. People who have not reached menopause may also need ovarian suppression.
Treatment may change when the disease develops resistance. Blood or tissue testing can look for alterations such as:
- ESR1: May support treatment with an oral estrogen receptor degrader.
- PIK3CA: May make selected PIK3CA-directed treatment appropriate.
- AKT1 or PTEN: May support an AKT-directed treatment.
- Inherited BRCA1 or BRCA2: May support the use of a PARP inhibitor.
The FDA approved imlunestrant in September 2025 and vepdegestrant in May 2026 for specific patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic disease after prior endocrine therapy. Eligibility differs between drugs and should be determined using approved testing.
Chemotherapy or an antibody-drug conjugate may be considered when hormone-based treatments no longer control the disease or a faster response is required.
HER2-Positive Advanced Breast Cancer
HER2-positive cancer produces excess HER2 protein, which encourages cancer-cell growth. HER2-targeted medicines block this signal or deliver a cancer-killing drug directly to HER2-expressing cells.
Treatments may include trastuzumab, pertuzumab, trastuzumab deruxtecan, tucatinib, and other HER2-directed options. The sequence depends on previous treatment, heart function, brain metastases, treatment response, and side effects.
In December 2025, the FDA approved trastuzumab deruxtecan with pertuzumab as a first-line treatment for eligible adults with unresectable or metastatic HER2-positive breast cancer. This illustrates why current oncology guidance matters in a rapidly changing treatment area.
Some HER2-targeted treatments can affect the heart or lungs. Patients should complete recommended heart monitoring and report new cough, breathlessness, fever, or chest symptoms promptly.
HER2-Low and HER2-Ultralow Cancer
Some tumors do not meet the criteria for HER2-positive cancer but still carry small amounts of the HER2 protein. These may be classified as HER2-low or HER2-ultralow.
These categories matter because selected antibody-drug conjugates can target even small amounts of HER2. In January 2025, the FDA expanded trastuzumab deruxtecan treatment to certain HR-positive, HER2-low or HER2-ultralow metastatic cancers that had progressed after endocrine therapy.
Patients whose older pathology report simply says “HER2-negative” may benefit from asking whether the sample was evaluated using current HER2-low and ultralow definitions.
Triple-Negative Advanced Breast Cancer
Triple-negative breast cancer lacks estrogen receptors, progesterone receptors, and HER2 overexpression. As a result, hormone therapy and traditional HER2-directed treatment are not effective.
Chemotherapy remains an important treatment. Pembrolizumab may be combined with chemotherapy for eligible patients whose tumors meet the required PD-L1 threshold.
Other options may include sacituzumab govitecan, PARP inhibitors for inherited BRCA-related cancer, trastuzumab deruxtecan for qualifying HER2-low disease, or clinical trials.
In May 2026, the FDA approved datopotamab deruxtecan for adults with unresectable or metastatic triple-negative breast cancer after prior systemic treatment. Its place in therapy depends on treatment history, eligibility, safety considerations, and oncology guidance.
Chemotherapy and Antibody-Drug Conjugates
Chemotherapy may be used across breast cancer subtypes when targeted or hormone-based treatments are unsuitable, have stopped working, or cannot provide sufficiently rapid disease control.
For metastatic disease, oncologists often use one chemotherapy medicine at a time. This may provide cancer control while reducing the combined toxicity associated with multi-drug regimens.
Antibody-drug conjugates combine a cancer-targeting antibody with chemotherapy. The antibody finds cells carrying a particular marker and delivers the attached drug to them.
These treatments can still affect healthy tissue. Possible concerns include low blood counts, nausea, fatigue, mouth sores, eye problems, nerve symptoms, or lung inflammation, depending on the medicine used.
PARP Inhibitors for BRCA-Related Cancer
People with an inherited BRCA1 or BRCA2 variant may be eligible for a PARP inhibitor. These medicines limit the ability of cancer cells to repair damaged DNA.
Olaparib and talazoparib are treatment options for selected patients with HER2-negative, BRCA-associated metastatic breast cancer. Genetic counselling can help patients understand what the result means for treatment and their relatives.
A tumor-only genetic result does not always confirm an inherited mutation. Germline testing using blood or saliva may be needed.
Surgery and Radiation Therapy
Surgery is often part of treatment for locally advanced breast cancer once the tumor has responded to initial systemic therapy.
In metastatic disease, surgery is less commonly used to control cancer throughout the body. It may still help manage a painful breast tumor, stabilize a weakened bone, relieve pressure, or treat a limited brain lesion.
Radiation therapy for advanced breast cancer may help relieve painful bone metastases, treat brain metastases, control bleeding, reduce pressure on nerves, manage spinal cord compression, and control a troublesome tumor in the breast or chest wall.
Treating a small number of metastatic tumors directly is sometimes considered for oligometastatic disease. The benefit remains dependent on the individual situation and should be discussed by a multidisciplinary team.
Bone and Brain Metastases
Cancer that has spread to bone may cause persistent pain, fractures, high calcium levels, or spinal cord compression. Bisphosphonates or denosumab may help reduce skeletal complications.
A dental evaluation is often recommended before bone-modifying therapy because these medicines can rarely cause damage to the jawbone.
Brain metastases may cause headaches, seizures, weakness, balance problems, confusion, speech changes, or vision problems. Treatment may include stereotactic radiation, whole-brain radiation, surgery, systemic treatment, or a combination.
Some HER2-targeted medicines have activity against brain metastases. Treatment selection depends on cancer subtype, previous therapy, the number and size of lesions, and whether symptoms are present.
Side Effects and Supportive Care
Side effects vary according to treatment. Possible problems include fatigue, nausea, diarrhea, low blood counts, infection, mouth sores, hair loss, nerve damage, joint symptoms, blood clots, heart changes, or lung inflammation.
New symptoms should be reported early. The oncology team may use supportive medicine, dose adjustments, rehabilitation, nutritional care, treatment breaks, or a different drug to make therapy more manageable.
Palliative care can begin at any stage of advanced cancer treatment. It supports pain control, sleep, appetite, breathing, emotional health, family communication, and caregiver needs. It does not mean that cancer-directed treatment must stop.
How Doctors Monitor Treatment?
CT, MRI, PET, or bone scans may be used to evaluate cancer. Blood tests can monitor blood counts, liver and kidney function, calcium levels, and treatment toxicity.
Tumor-marker blood tests may offer additional information for some patients. However, they should usually be interpreted with symptoms and imaging rather than used alone to decide whether treatment is working.
Treatment often continues while it controls the cancer and side effects remain acceptable. If the disease progresses, doctors may repeat biomarker testing, choose another treatment, or discuss a clinical trial.
Living With Advanced Breast Cancer
The outlook differs greatly between patients. Tumor subtype, metastatic location, treatment response, general health, and access to newer therapies can all influence survival.
Population statistics describe large groups and cannot predict exactly how long an individual will live. Some people respond to treatment for years and move through several effective therapies.
Useful support may include:
- Oncology social work
- Mental health counselling
- Pain and symptom management
- Rehabilitation or physical therapy
- Nutrition advice
- Financial and insurance assistance
- Caregiver support
- Advance care planning
Advance care planning is not the same as stopping treatment. It allows patients to document their priorities and preferred medical care before an emergency occurs.
When a Second Opinion May Help?
A second opinion may be useful after the initial advanced breast cancer diagnosis, before a major treatment change, or when genomic testing identifies a complex alteration.
Consulting a breast medical oncologist may help confirm pathology, review treatment sequencing, identify clinical trials, and determine whether surgery or radiation has a role.
Treatment does not always need to be delayed for long. Medical records, pathology slides, scan images, and molecular test results can often be shared electronically.
When to Seek Urgent Medical Care?
During advanced breast cancer treatment, contact the oncology team immediately or seek emergency care for fever during chemotherapy or immune-suppressing therapy, sudden chest pain, breathing difficulty, seizures, confusion, one-sided weakness, or a severe and rapidly worsening headache. Urgent assessment is also needed for new severe back or neck pain, leg weakness, numbness, difficulty walking, loss of bladder or bowel control, uncontrolled bleeding, repeated vomiting, inability to drink, sudden severe bone pain, inability to bear weight, yellow skin, or rapidly increasing abdominal swelling.
New back pain with weakness, numbness, walking difficulty, or bladder changes may indicate metastatic spinal cord compression. This is a medical emergency that requires immediate assessment.
Questions to Ask Your Oncologist
- Is my cancer locally advanced or metastatic?
- What are the current ER, PR and HER2 results?
- Has the cancer been tested for HER2-low or HER2-ultralow status?
- Should a metastatic tumor be biopsied?
- Which inherited and tumor genetic tests are appropriate?
- What is the goal of this treatment?
- How will we know whether it is working?
- Which side effects need an urgent call?
- Are radiation or surgery needed?
- Is a clinical trial suitable now or later?
- Would a second opinion change my options?
- How can palliative care support me during treatment?
Conclusion
Advanced breast cancer treatment is personalized according to whether the disease is locally advanced or metastatic, its biological subtype, biomarkers, previous treatment, symptoms, and patient priorities.
Options may include hormone therapy, chemotherapy, immunotherapy, HER2-directed medicines, antibody-drug conjugates, PARP inhibitors, surgery, radiation, and supportive care. Repeat testing and current specialist advice are valuable because available treatments continue to change.
FAQS
Yes. Locally advanced breast cancer may be treated with curative intent. Metastatic disease is usually treated to control growth, relieve symptoms, and preserve quality of life.
There is no single best treatment. The plan depends on stage, hormone receptor and HER2 status, genetic changes, previous therapy, symptoms, metastatic sites, and overall health.
Not always. Advanced breast cancer may include locally advanced stage III disease and metastatic stage IV cancer that has spread to distant organs.
No. Hormone receptor-positive cancer may initially receive endocrine therapy with a targeted medicine. Chemotherapy may be needed when rapid control is necessary or other treatments stop working.
Some patients achieve a complete response, meaning tests show no detectable cancer. Continued treatment and monitoring are generally required because microscopic cancer cells may remain.
A new biopsy can confirm metastasis and reveal whether ER, PR, or HER2 status has changed. Updated results may provide different targeted treatment options.
Treatment commonly continues while it controls the disease and side effects remain manageable. Doctors may change therapy if cancer progresses or toxicity becomes unacceptable.
Yes. Radiation may relieve bone pain, treat brain metastases, control bleeding, reduce pressure on nerves, protect the spinal cord, or manage a troublesome tumor.
Targeted therapy acts on specific cancer features, such as HER2, CDK4/6, PIK3CA, AKT, ESR1, or PARP pathways. Biomarker testing helps determine eligibility.
Clinical trials may provide access to emerging treatments. Eligibility depends on cancer subtype, biomarkers, previous treatments, overall health, location, and the trial’s requirements.